Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2006-07-11
2006-07-11
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S234100, C424S190100, C424S192100, C424S184100, C424S203100, C424S237100, C530S350000, C530S300000, C530S806000, C530S825000, C530S807000, C514S002600
Reexamination Certificate
active
07074416
ABSTRACT:
Recombinant hybrid streptococcal M protein antigens are provided which elicit protective antibodies against Group A streptococci and prevent rheumatic fever. Recombinant hybrid genes which encode the antigen are provided. Vaccine compositions and methods of administering the compositions are provided to elicit immunity against Group A streptococci.
REFERENCES:
patent: 4284537 (1981-08-01), Beachey
patent: 4454121 (1984-06-01), Beachey
patent: 4521334 (1985-06-01), Beachey
patent: 4597967 (1986-07-01), Beachey
patent: 4705684 (1987-11-01), Beachey
patent: 4886663 (1989-12-01), Houghten
patent: 4919930 (1990-04-01), Beachey et al.
patent: 5124153 (1992-06-01), Beachey et al.
patent: 5149657 (1992-09-01), Maugh et al.
patent: 5182109 (1993-01-01), Tamura et al.
patent: 5279937 (1994-01-01), Rowe
patent: 5306492 (1994-04-01), Porro
patent: 5763733 (1998-06-01), Whitlow et al.
patent: 6063386 (2000-05-01), Dale et al.
patent: 6072036 (2000-06-01), Marasco et al.
patent: 6419932 (2002-07-01), Dale
patent: 0035384 (1981-09-01), None
patent: WO 91/02799 (1991-03-01), None
patent: WO 91/04036 (1991-04-01), None
Newton et al. Infect. Immun. 59: 2158-2165, 1991.
Beachey et al. J. Immunol. 136: 2287-2292, 1986b.
The American Heritage Dictionary, Second College Edition, p. 805, 1976.
Ada, G.L.,Fundamental Immunology, 2ndEdition, William E. Paul (ed.), Raven Press Ltd., New York, 1989, Chapter 36, “Vaccines,” pp. 1010-1011.
Baird et al., “Epitopes of Group A Streptococcal M Protein Shared With Antigens of Articular Cartilage and Synovium,”The Journal of Immunology146(9): 3132-3137, May 1, 1991.
Beall et al., “Sequencingemm-Specific PCR Products for Routine and Accurate Typing of Group A Streptococci,”Journal of Clinical Microbiology34(4): 953-958, Apr. 1996.
Beachey et al., “Peptic Digestion of Streptococcal M Protein II. Extraction of M Antigen from Group A Streptococci With Pepsin,”Infection and Immunity9(5): 891-896, May 1974.
Beachey et al., “Human Immune Response to Immunization with a Structurally Defined Polypeptide Fragment of Streptococcal M Protein,”J. Exp. Med. 150: 862-877, Oct. 1979.
Beachey et al., “Opsonic Antibodies Evoked by Hybrid Peptide Copies of Types 5 and 24 Streptococcal M Proteins Synthesized in Tandem,”J. Exp. Med . 168: 1451-1458, Jun. 1986.
Beachey et al., “Purification and Properties of M Protein Extracted From Group A Streptococci With Pepsin: Covalent Structure of the Amino Terminal Region of Type 24 M Antigen,”The Journal of Experimental Medicine 145: 1469-1483, 1977.
Beachey et al., “Type-specific protective immunity evoked by synthetic peptide ofStreptococcus pyogenesM protein,”Nature 292: 457-459, Jul. 1981.
Beachey et al., “Repeating covalent structure of streptococcal M protein,”Proc. Natl. Acad. Sci. USA 75(7): 3163-3167, Jul. 1978.
Beachey et al., “Repeating Covalent Structure and Protective Immunogenicity of Native and Synthetic Polypeptide Fragments of Type 24 Streptococcal M Protein,”The Journal of Biological Chemistry258(21): 13250-13257, Nov. 10, 1983.
Beachey et al., “Primary Structure of Protective Antigens of Type 24 Streptococcal M Protein,”The Journal of Biological Chemistry255(13):6284-6289, Jul. 10, 1980.
Beachey et al., “Immunogenicity in Animals and Man of a Structurally Defined Polypeptide of Streptococcal M Protein,”Transactions of the Association of American Physiciansvol. XCII: 346-354, 1979.
Beachey et al., “Separation of the Type Specific M Protein From Toxic Gross Reactive Antigens of Group A Streptococci,”Transactions of the Association of American Physicians 90thSessionvol. XC: 390-400, 1977.
Beachey et al., “Protective Immunogenicity and T Lymphocyte Specificity of a Trivalent hybrid Peptide Containing NH2- Terminal Sequences of Types 5, 6, and 24 M Proteins Synthesized in Tandem,”Journal of Experimental Medicine 166: 647-656, Sep. 1987.
Beachey and Stollerman, “Toxic Effects of Streptococci M Protein on Platelets and Polymorphonuclear Leukocytes in Human Blood,”The Journal of Experimental Medicine 134: 351-365, 1971.
Beachey and Stollerman, “Mediation of Cytotoxic Effects of Streptococcal M Protein by Nontype-Specific Antibody in Human Sera,”The Journal of Clinical Investigation 52: 2563-2570, Oct. 1973.
Beachey and Seyer, “Protective and Nonprotective Epitopes of Chemically Synthesized Peptides of the NH2-Terminal Region of Type 6 Streptococcal M Protein,”The Journal of Immunology 136(6):2287-2292, Mar. 15, 1986.
Beachey and Seyer,Seminars in Infectious Disease. vol. IV Bacterial Vaccines, Thieme-Stratton Inc., New York, New York, 1982, Chapter 57, “Primary Structure and Immunochemistry of Group A Streptococcal M. Proteins,” pp. 401-410.
Beachey and Ofek, “Epithelial Cell Binding of Group A Streptococci by Lipoteichoic Acid on Fimbriae Denuded of M Protein,”The Journal of Experimental Medicine 143: 759-771, 1976.
Blenden et al., “Growth ofListeria monocytogenesin a Corn Silage Extract Medium,”Am. J. Vet. Res. 29(11): 2237-2242, Nov. 1968.
Bricas et al.,Peptides, Beyerman et al. (eds.), North-Holland Publishing Company, Amsterdam, 1967, “Structure et Synthese de la Subunite Peptidique de la Paroi de Trois Bacteries Gram-Positif,” pp. 286-292 (+Biological Abstracts 50(4): Abstract No. 20361, 1936).
Bronze et al., “Protective and Heart-Crossreactive Epitopes Located Within the NH2Terminus of Type 19 Streptococcal M Protein,”J. Exp. Med . 167(6): 1849-1859, Jun. 1, 1988.
Chou and Fasman, “Prediction of Protein Conformation,”Biochemistry13(2): 222-245, 1974.
Clements, J.D., “Construction of a Nontoxic Fusion Peptide for Immunization againstEscherichia coliStrains That Produce Heat-Labile and Heat-Stable Enterotoxins,”Infection and Immunity58: 1159-1166, 1990.
Cunningham and Beachey, “Peptic Digestion of Streptococcal M Protein I. Effect of Digestion at Suboptimal pH upon the Biological and Immunochemical Properties of Purified M Protein Extracts,”Infection and Immunity 9(2): 244-248, Feb. 1974.
Cunningham et al., “Human and Murine Antibodies Cross-Reactive With Streptococcal M Protein and Myosin Recognize the Sequence Gln-Lys-Ser-Lys-Gln in M Protein,”The Journal of Immunology 143(8): 2677-2683, Oct. 15, 1989.
Dale, J.B., “Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments,”Vaccine 17: 193-200, 1999.
Dale, J.B., “Group A Streptococcal Vaccines,”New Vaccines and New Vaccine Technology13(1): 227-243, Mar. 1999.
Dale, J.B., “Group A Steptococcal Vaccines.”Pediatric Annals 27(5): 301-308, May 1998.
Dale and Beachey, “Multiple, Heart-Cross-Reactive Epitopes of Streptococcal M Proteins,”Journal of Experimental Medicine 161: 113-122, Jan. 1985.
Dale and Beachey, “Localization of Protective Epitopes of the Amino Terminus of Type 5 Streptococcal M Protein,”Journal of Experimental Medicine163: 1191-1202, May 1986.
Dale and Beachey, “Epitopes of Streptococcal M Proteins Shared With Cardiac Myosin,”Journal of Experimental Medicine 162: 583-591, Aug. 1985.
Dale and Beachey, “Sequence of Myosin-Crossreactive Epitopes of Streptococcal M Protein,”Journal of Experimental Medicine 164: 1785-1790, Nov. 1986.
Dale et al., “Blastogenic Responses of Human Lymphocytes to Structurally Defined Polypeptide Fragments of Streptococcal M Protein,”The Journal of Immunology 126(4): 1499-1505, Apr. 1981.
Dale et al., “Heterogeneity of Type-Specific and Cross-Reactive Antigenic Determinants Within a Single M Protein of Group A Streptococci,”The Journal of Experimental Medicine 151: 1026-1083, 1980.
Dale et al., “Type-Specific Immunogenicity of a Chemically Synthesized Peptide Fragment of Type 5 Streptococcal M P
Devi S.
Seed IP Law Group PLLC
University of Tennessee Research Foundation
LandOfFree
Antigen of hybrid M protein and carrier for group A... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antigen of hybrid M protein and carrier for group A..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antigen of hybrid M protein and carrier for group A... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3537788